A promising hypoxia-inducible suicide gene therapy strategy for prostate cancer
Citation:
Laure Marignol, 'A promising hypoxia-inducible suicide gene therapy strategy for prostate cancer', [thesis], Trinity College (Dublin, Ireland). School of Medicine. Discipline of Clinical Medicine, 2008, pp 377Download Item:
Abstract:
Gene therapy targeted to hypoxic tumour cells may allow selective killing of malignant cells. The induction of gene expression under hypoxic conditions is governed by the activation of hypoxia-inducible factor 1 and its subsequent binding to hypoxia response elements. The HREs of a number of oxygen- responsive genes, including vascular endothelial growth factor (VEGF) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were cloned upstream of the cytosine deaminase (CD) gene. These constructs will drive the expression of this prodrug activation enzyme, which converts inactive 5- fluorocytosine (5-FC) to active 5-fluorouracil (5-FU), allowing selective killing of vector containing cells. 5-FU is also a radiosensitising agent, so specific expression of this agent in prostate cancer cells can also potentiate radiotherapy approaches in prostate cancer.
Author: Marignol, Laure
Advisor:
Lawler, MarkHollywood, Donal
Qualification name:
Doctor of Philosophy (Ph.D.)Publisher:
Trinity College (Dublin, Ireland). School of Medicine. Discipline of Clinical MedicineNote:
TARA (Trinity’s Access to Research Archive) has a robust takedown policy. Please contact us if you have any concerns: rssadmin@tcd.ieType of material:
thesisCollections
Availability:
Full text availableMetadata
Show full item recordLicences: